News Daily News SYNTAX Score Should Not Guide Revascularization Strategy in FREEDOM-Like Patients Michael O'Riordan December 04, 2018
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018
News Conference News AHA 2018 REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides Todd Neale November 10, 2018
News Conference News AHA 2018 VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer Shelley Wood November 10, 2018
News Daily News ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom Michael O'Riordan November 07, 2018
News Conference News TCT 2018 RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation Todd Neale September 26, 2018
News Conference News TCT 2018 Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials Michael O'Riordan September 25, 2018
News Conference News TCT 2018 Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation Todd Neale September 25, 2018
News Conference News TCT 2018 OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients Todd Neale September 24, 2018
News Daily News Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients L.A. McKeown August 09, 2018
News Daily News One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL Michael O'Riordan February 12, 2018